NCT05164250: Compassionate Use (CU) of REGN5458 for Relapsed or Refractory Multiple Myeloma (MM)
Updated: Sep 24, 2022
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Provide Compassionate Use' of REGN5458 for Patients with Relapsed or Refractory Multiple Myeloma
Drug: REGN5458
Sponsor
ClinicalTrials.gov Identifier: NCT05164250
Official Title: Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
First Posted : December 20, 2021
Click here for details on ClinicalTrials.gov
Linvoseltamab (Code C158504)
Anti-BCMA x Anti-CD3 BiTE REGN5458
Anti-BCMA/CD3 BiTE Antibody REGN5458
Bispecific BCMA x CD3 T-cell Engaging Antibody REGN5458
BiTE Antibody REGN5458
Linvoseltamab
LINVOSELTAMAB
REGN 5458
REGN-5458
REGN5458
Related Posts
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM
NCT04083534: Phase 1/2: First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed RRMM
NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM